You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDexbrompheniramine
Accession NumberDB00405  (APRD00770)
TypeSmall Molecule
GroupsApproved
DescriptionDexbrompheniramine maleate is an antihistamine used to treat allergic conditions such as hay fever or urticaria.
Structure
Thumb
Synonyms
(+)-Brompheniraminum
(+)-parabromdylamine
(R)-3-(4-Bromophenyl)-3-(2-pyridyl)propyldimethylamine
(S)-(+)-Brompheniramine
(S)-Brompheniramine
3-(4-bromophenyl)- N,N-dimethyl- 3-pyridin-2-yl-propan-1-amine
D-Brompheniramine
Desbrofeniramina
Dexbromfeniramina
Dexbrompheniramin
Dexbromphéniramine
Dexbrompheniraminum
Parabromodylamine
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ala-hist IrTablet2 mg/1OralPoly Pharmaceuticals, Inc.2011-08-22Not applicableUs
PediaventSyrup2 mg/5mLOralCar Win Pharmaceutical Associates, Llc2014-08-04Not applicableUs
PediaventTablet, chewable1 mg/1OralCar Win Pharmaceutical Associates, Llc2014-08-05Not applicableUs
Unapproved/Other Products Not Available
International Brands
NameCompany
DisophrolSchering
DrixoralSchering
Brand mixtures
NameLabellerIngredients
ActiconActipharma, Inc
ActidogesicActipharma, Inc
Ala-hist PEPoly Pharmaceuticals, Inc.
Alahistdm DMPoly Pharmaceuticals, Inc.
Bionatuss DxpAdvanced Generic Corporation
Chlo HistR. A. Mc Neil Company
Chlo TussR.A. Mc Neil Company
ConexLlorens Pharmaceuticals International Division
Coricidin 'd' Nasal and Sinus CongestionSchering Plough Healthcare Products Canada, A Division Of Schering Canada Inc.
Coricidin D Nasal and Sinus Congestion TabletsSchering Plough Healthcare Products Canada, A Division Of Schering Canada Inc.
DallergyLaser Pharmaceuticals, LLC
Dexbrompherniramine Maleate and Pseudoephedrine Sulfate 6mg/120mgKvk Tech, Inc.
DologenKramer Novis
Dologen 325Kramer Novis
Dologesic DFLlorens Pharmaceutical International Division
Dologesic NfLlorens Pharmaceutical International Division
Drixoral Cold & SinusBayer Inc Consumer Care
Drixoral Day/night - Srt/tabsSchering Plough Canada Inc
Drixoral SyrupSchering Plough Canada Inc
Drixtab TabSchering Plough Canada Inc
G-con-XMc Laren Medical
G-dologenKramer Novis
G-P-tuss DxpKramer Novis
M-end DmxR. A. Mc Neil Company
M-end Max DR.A. Mc Neil Company
Panatuss DxpSeyer Pharmatec, Inc.
Panatuss Pediatric Drops DxpSeyer Pharmatec, Inc.
Supress AKramer Novis
Salts
Name/CASStructureProperties
Dexbrompheniramine maleate
2391-03-9
Thumb
  • InChI Key: SRGKFVAASLQVBO-DASCVMRKSA-N
  • Monoisotopic Mass: 434.08412
  • Average Mass: 435.318
DBSALT001411
Categories
UNII75T64B71RP
CAS number132-21-8
WeightAverage: 319.239
Monoisotopic: 318.073161265
Chemical FormulaC16H19BrN2
InChI KeyZDIGNSYAACHWNL-HNNXBMFYSA-N
InChI
InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m0/s1
IUPAC Name
[(3S)-3-(4-bromophenyl)-3-(pyridin-2-yl)propyl]dimethylamine
SMILES
CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C1=CC=CC=N1
Pharmacology
IndicationFor treatment and relief of symptoms of allergies, hay fever, and colds
Structured Indications
PharmacodynamicsIn allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H1-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Dexbrompheniramine is a histamine H1 antagonist (or more correctly, an inverse histamine agonist) of the alkylamine class. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.
Mechanism of actionDexbrompheniramine competitively binds to the histamine H1-receptor. It competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.
TargetKindPharmacological actionActionsOrganismUniProt ID
Histamine H1 receptorProteinyes
antagonist
HumanP35367 details
Related Articles
AbsorptionAntihistamines are well absorbed from the gastrointestinal tract after oral administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic (cytochrome P-450 system), some renal.

Route of eliminationNot Available
Half life25 hours
ClearanceNot Available
ToxicitySigns of an overdose include fast or irregular heartbeat, mental or mood changes, tightness in the chest, and unusual tiredness or weakness.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Dexbrompheniramine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Dexbrompheniramine.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Dexbrompheniramine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Dexbrompheniramine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Dexbrompheniramine.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Dexbrompheniramine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Dexbrompheniramine.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Dexbrompheniramine.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Dexbrompheniramine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Dexbrompheniramine.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Dexbrompheniramine.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Dexbrompheniramine.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dexbrompheniramine.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Dexbrompheniramine.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Dexbrompheniramine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dexbrompheniramine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Dexbrompheniramine.Experimental
AmphetamineAmphetamine may decrease the sedative activities of Dexbrompheniramine.Approved, Illicit
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dexbrompheniramine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Dexbrompheniramine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Dexbrompheniramine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Dexbrompheniramine.Vet Approved
AzelastineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Dexbrompheniramine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Dexbrompheniramine.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Dexbrompheniramine.Approved
BenzphetamineBenzphetamine may decrease the sedative activities of Dexbrompheniramine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Dexbrompheniramine.Approved
Benzylpenicilloyl PolylysineDexbrompheniramine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Dexbrompheniramine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dexbrompheniramine.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Dexbrompheniramine.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dexbrompheniramine.Approved, Investigational
BuprenorphineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dexbrompheniramine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dexbrompheniramine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Dexbrompheniramine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Dexbrompheniramine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Dexbrompheniramine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Dexbrompheniramine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dexbrompheniramine.Approved, Illicit, Vet Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dexbrompheniramine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Dexbrompheniramine.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dexbrompheniramine.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Dexbrompheniramine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Dexbrompheniramine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dexbrompheniramine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Dexbrompheniramine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dexbrompheniramine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Chlorphenamine.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Dexbrompheniramine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dexbrompheniramine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dexbrompheniramine.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dexbrompheniramine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dexbrompheniramine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Dexbrompheniramine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Dexbrompheniramine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Dexbrompheniramine.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dexbrompheniramine.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dexbrompheniramine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Dexbrompheniramine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dexbrompheniramine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dexbrompheniramine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dexbrompheniramine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dapoxetine.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Dexbrompheniramine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Dexbrompheniramine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Dexbrompheniramine.Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dexbrompheniramine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Dexbrompheniramine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Dexbrompheniramine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dexbrompheniramine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Dexbrompheniramine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Dexbrompheniramine.Approved, Illicit, Vet Approved
DiethylpropionDiethylpropion may decrease the sedative activities of Dexbrompheniramine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dexbrompheniramine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Dexbrompheniramine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Dexbrompheniramine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dexbrompheniramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dexbrompheniramine.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Dexbrompheniramine.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Dexbrompheniramine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Dexbrompheniramine.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dexbrompheniramine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Dexbrompheniramine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Dexbrompheniramine.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Efavirenz.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Dexbrompheniramine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Dexbrompheniramine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dexbrompheniramine.Approved
EthanolDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dexbrompheniramine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Dexbrompheniramine.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Dexbrompheniramine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dexbrompheniramine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Dexbrompheniramine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Dexbrompheniramine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Dexbrompheniramine.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dexbrompheniramine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Dexbrompheniramine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dexbrompheniramine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dexbrompheniramine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Dexbrompheniramine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Dexbrompheniramine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dexbrompheniramine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dexbrompheniramine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dexbrompheniramine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Dexbrompheniramine.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dexbrompheniramine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Dexbrompheniramine.Approved, Illicit
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dexbrompheniramine.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dexbrompheniramine.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Dexbrompheniramine.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Dexbrompheniramine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dexbrompheniramine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Dexbrompheniramine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Dexbrompheniramine.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dexbrompheniramine.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dexbrompheniramine.Approved, Investigational
HydrocodoneDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dexbrompheniramine.Approved, Illicit
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Dexbrompheniramine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Indalpine.Investigational, Withdrawn
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Dexbrompheniramine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dexbrompheniramine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Dexbrompheniramine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Dexbrompheniramine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Dexbrompheniramine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dexbrompheniramine.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dexbrompheniramine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dexbrompheniramine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Dexbrompheniramine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Dexbrompheniramine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Dexbrompheniramine.Illicit
LoratadineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dexbrompheniramine.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dexbrompheniramine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Dexbrompheniramine.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dexbrompheniramine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Dexbrompheniramine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Dexbrompheniramine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Dexbrompheniramine.Approved
MephedroneMephedrone may decrease the sedative activities of Dexbrompheniramine.Investigational
MephentermineMephentermine may decrease the sedative activities of Dexbrompheniramine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dexbrompheniramine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dexbrompheniramine.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dexbrompheniramine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Dexbrompheniramine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Dexbrompheniramine.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative activities of Dexbrompheniramine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Dexbrompheniramine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Dexbrompheniramine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dexbrompheniramine.Approved
MethotrimeprazineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dexbrompheniramine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dexbrompheniramine.Approved
MetyrosineDexbrompheniramine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Dexbrompheniramine.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved, Investigational
MirtazapineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAMMDA may decrease the sedative activities of Dexbrompheniramine.Experimental, Illicit
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Dexbrompheniramine.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dexbrompheniramine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dexbrompheniramine.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dexbrompheniramine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Dexbrompheniramine.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Dexbrompheniramine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dexbrompheniramine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dexbrompheniramine.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Dexbrompheniramine.Approved, Illicit
OrphenadrineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Dexbrompheniramine.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dexbrompheniramine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Dexbrompheniramine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Dexbrompheniramine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dexbrompheniramine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dexbrompheniramine.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dexbrompheniramine.Approved
ParaldehydeDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Paroxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dexbrompheniramine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dexbrompheniramine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved
PerazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Dexbrompheniramine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dexbrompheniramine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dexbrompheniramine.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dexbrompheniramine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Dexbrompheniramine.Approved
PhenterminePhentermine may decrease the sedative activities of Dexbrompheniramine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Dexbrompheniramine.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Dexbrompheniramine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Dexbrompheniramine.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pomalidomide.Approved
PramipexoleDexbrompheniramine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Dexbrompheniramine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Dexbrompheniramine.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dexbrompheniramine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Dexbrompheniramine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Dexbrompheniramine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dexbrompheniramine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Dexbrompheniramine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dexbrompheniramine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Dexbrompheniramine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Dexbrompheniramine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dexbrompheniramine.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Dexbrompheniramine.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative activities of Dexbrompheniramine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Dexbrompheniramine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dexbrompheniramine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dexbrompheniramine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dexbrompheniramine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dexbrompheniramine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Dexbrompheniramine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ritanserin.Investigational
RitobegronRitobegron may decrease the sedative activities of Dexbrompheniramine.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Dexbrompheniramine.Vet Approved
RopiniroleDexbrompheniramine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dexbrompheniramine.Approved
RotigotineDexbrompheniramine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dexbrompheniramine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Dexbrompheniramine.Experimental
Sage 547The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dexbrompheniramine.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Dexbrompheniramine.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dexbrompheniramine.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dexbrompheniramine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dexbrompheniramine.Approved
SuvorexantDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dexbrompheniramine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Dexbrompheniramine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Dexbrompheniramine.Investigational
ThalidomideDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dexbrompheniramine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Dexbrompheniramine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dexbrompheniramine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dexbrompheniramine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tiapride.Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Dexbrompheniramine.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dexbrompheniramine.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Dexbrompheniramine.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dexbrompheniramine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Dexbrompheniramine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dexbrompheniramine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Dexbrompheniramine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Dexbrompheniramine.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dexbrompheniramine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dexbrompheniramine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Dexbrompheniramine.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Venlafaxine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vigabatrin.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Dexbrompheniramine.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Dexbrompheniramine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dexbrompheniramine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dexbrompheniramine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Dexbrompheniramine.Vet Approved
ZolpidemDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Dexbrompheniramine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Dexbrompheniramine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dexbrompheniramine.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Walter, L.A.; U.S. Patents 3,061,517; October 30, 1962; and 3,030,371; April 17, 1962; both assigned to Schering Corporation.

General ReferencesNot Available
External Links
ATC CodesR06AB56R06AB06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9648
Blood Brain Barrier+0.9576
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.6242
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.93
Renal organic cation transporterInhibitor0.7955
CYP450 2C9 substrateNon-substrate0.8345
CYP450 2D6 substrateSubstrate0.8346
CYP450 3A4 substrateSubstrate0.5898
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8398
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7748
Ames testNon AMES toxic0.9351
CarcinogenicityNon-carcinogens0.9349
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.0758 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9121
hERG inhibition (predictor II)Inhibitor0.7207
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Schering corp sub schering plough corp
Packagers
Dosage forms
FormRouteStrength
TabletOral2 mg/1
SyrupOral
TabletOral
Tablet, extended releaseOral
Tablet; tablet, extended releaseOral
LiquidOral
SyrupOral2 mg/5mL
Tablet, chewableOral1 mg/1
Prices
Unit descriptionCostUnit
Ala-hist ir 2 mg tablet0.82USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point113-115US. Patent 3,030,371.
logP3.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0127 mg/mLALOGPS
logP3.63ALOGPS
logP3.75ChemAxon
logS-4.4ALOGPS
pKa (Strongest Basic)9.48ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area16.13 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity83.67 m3·mol-1ChemAxon
Polarizability31.84 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pheniramines. These are compounds containing a pheniramine moiety, which is structurally characterized by the presence of a 2-benzylpyridine linked to an dimethyl(propyl)amine to form a dimethyl[3-phenyl-3-(pyridin-2-yl)propyl]amine skeleton.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassPheniramines
Direct ParentPheniramines
Alternative Parents
Substituents
  • Pheniramine
  • Phenylpropylamine
  • Aralkylamine
  • Halobenzene
  • Bromobenzene
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl bromide
  • Heteroaromatic compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organobromide
  • Organohalogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. McLeod RL, Mingo G, O'Reilly S, Ruck LA, Bolser DC, Hey JA: Antitussive action of antihistamines is independent of sedative and ventilation activity in the guinea pig. Pharmacology. 1998 Aug;57(2):57-64. [PubMed:9691225 ]
  2. Bokesoy TA, Onaran HO: Atypical Schild plots with histamine H1 receptor agonists and antagonists in the rabbit aorta. Eur J Pharmacol. 1991 May 2;197(1):49-56. [PubMed:1680053 ]
  3. Onaran HO, Bokesoy TA: Kinetics of antagonism at histamine-H1 receptors in isolated rabbit arteries. Naunyn Schmiedebergs Arch Pharmacol. 1990 Apr;341(4):316-23. [PubMed:1970615 ]
  4. Yanni JM, Stephens DJ, Parnell DW, Spellman JM: Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use. J Ocul Pharmacol. 1994 Winter;10(4):665-75. [PubMed:7714410 ]
  5. Sadofsky LR, Campi B, Trevisani M, Compton SJ, Morice AH: Transient receptor potential vanilloid-1-mediated calcium responses are inhibited by the alkylamine antihistamines dexbrompheniramine and chlorpheniramine. Exp Lung Res. 2008 Dec;34(10):681-93. doi: 10.1080/01902140802339623. [PubMed:19085565 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:47